Quality Systems – Page 37

Supplier qualification gap during scale-up – how to prevent recall triggers

Preventing Recall Triggers from Supplier Qualification Gaps During Scale-Up In the increasingly complex world of pharmaceutical production, suppliers play a critical role in ensuring quality and compliance. However, gaps in…

AE reporting non-compliance during signal review – CAPA for PV system weaknesses

Investigating AE Reporting Non-Compliance During Signal Review in Pharmacovigilance Systems In an increasingly regulated environment, the timely and accurate reporting of adverse events (AEs) is critical for patient safety and…

Stability impact underestimated during scale-up – how to prevent recall triggers

Understanding the Underestimated Stability Impact During Scale-Up and Preventing Recall Triggers In pharmaceutical manufacturing, the scale-up process is critical for transitioning from small-scale development to full-scale production. However, misjudging the…

Literature surveillance failure during audit response – how to strengthen benefit–risk documentation

Strengthening Benefit-Risk Documentation After Literature Surveillance Failures Pharmaceutical companies are under constant scrutiny to ensure that their pharmacovigilance activities adhere to regulatory standards. A common challenge arises when literature surveillance…

Stability impact underestimated during market launch – regulatory risk analysis and mitigation

Analyzing the Underestimated Stability Impact During Market Launch: A Risk Assessment Approach In the pharmaceutical industry, ensuring the stability of products before market launch is paramount. However, there are instances…

Case processing backlog during inspection – CAPA for PV system weaknesses

Addressing the Challenges of Case Processing Backlog During Inspections In the dynamic landscape of pharmaceutical manufacturing and regulatory compliance, unexpected backlogs in case processing during inspections can trigger significant operational…

Container closure integrity risk during scale-up – inspection evidence expectations

Assessing Container Closure Integrity Risks During Scale-Up: Evidence and Inspection Readiness As pharmaceutical organizations transition from clinical trial phases to full-scale production, the risk associated with container closure integrity (CCI)…

Case processing backlog during signal review – inspection questioning scenarios

Addressing Case Processing Backlogs During Signal Review: An Investigative Approach In the complex world of pharmacovigilance, maintaining case processing timelines is crucial for ensuring drug safety and compliance. However, a…

Material specification drift during supplier change – inspection evidence expectations

“`html Responding to Material Specification Drift During Supplier Changes: An Investigation Framework Pharmaceutical manufacturing is often challenged by issues related to material specification drift, especially during supplier changes. These can…

Literature surveillance failure during benefit–risk assessment – inspection questioning scenarios

Addressing Literature Surveillance Failures in Benefit-Risk Assessments: An Investigative Approach In the pharmaceutical industry, ensuring compliance with Good Manufacturing Practices (GMP) during literature surveillance is crucial for maintaining robust benefit-risk…

Artwork change error during development – documentation gaps regulators question

Investigation of Artwork Change Errors During Development: Addressing Documentation Gaps for Regulatory Compliance In the dynamic environment of pharmaceutical packaging development, unexpected errors can arise, particularly concerning artwork changes. Such…

Literature surveillance failure during inspection – regulatory enforcement risk and mitigation

Understanding and Mitigating Literature Surveillance Failures During Regulatory Inspections In today’s competitive pharmaceutical landscape, literature surveillance is a critical component of maintaining regulatory compliance and ensuring that product safety information…